BPMC Blueprint Medicines Corp

Price (delayed)

$94.93

Market cap

$5.54B

P/E Ratio

16.23

Dividend/share

N/A

EPS

$5.85

Enterprise value

$4.92B

Sector: Healthcare
Industry: Biotechnology

Highlights

The net income has soared by 188% YoY and by 3.6% QoQ
Blueprint Medicines's EPS has surged by 179% YoY
Blueprint Medicines's equity has surged by 105% YoY but it has decreased by 4.8% QoQ

Key stats

What are the main financial stats of BPMC
Market
Shares outstanding
58.34M
Market cap
$5.54B
Enterprise value
$4.92B
Valuations
Price to earnings (P/E)
16.23
Price to book (P/B)
3.93
Price to sales (P/S)
6.81
EV/EBIT
15.3
EV/EBITDA
14.73
EV/Sales
6.08
Earnings
Revenue
$809.14M
EBIT
$321.75M
EBITDA
$334.27M
Free cash flow
$368.78M
Per share
EPS
$5.85
Free cash flow per share
$6.36
Book value per share
$24.16
Revenue per share
$13.95
TBVPS
$28.01
Balance sheet
Total assets
$1.63B
Total liabilities
$225.37M
Debt
$87.67M
Equity
$1.4B
Working capital
$825.27M
Liquidity
Debt to equity
0.06
Current ratio
8.34
Quick ratio
8.01
Net debt/EBITDA
-1.84
Margins
EBITDA margin
41.3%
Gross margin
99.9%
Net margin
40.2%
Operating margin
39.8%
Efficiency
Return on assets
22.7%
Return on equity
27.3%
Return on invested capital
38.2%
Return on capital employed
21.3%
Return on sales
39.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BPMC stock price

How has the Blueprint Medicines stock price performed over time
Intraday
1.88%
1 week
-1.44%
1 month
2.08%
1 year
57.74%
YTD
-15.35%
QTD
-2.37%

Financial performance

How have Blueprint Medicines's revenue and profit performed over time
Revenue
$809.14M
Gross profit
$808.64M
Operating income
$322.13M
Net income
$325.12M
Gross margin
99.9%
Net margin
40.2%
The net income has soared by 188% YoY and by 3.6% QoQ
The operating income has soared by 184% YoY and by 4.3% from the previous quarter
BPMC's net margin has soared by 108% year-on-year
The operating margin has soared by 107% YoY and by 2.3% from the previous quarter

Growth

What is Blueprint Medicines's growth rate over time

Valuation

What is Blueprint Medicines stock price valuation
P/E
16.23
P/B
3.93
P/S
6.81
EV/EBIT
15.3
EV/EBITDA
14.73
EV/Sales
6.08
Blueprint Medicines's EPS has surged by 179% YoY
Blueprint Medicines's equity has surged by 105% YoY but it has decreased by 4.8% QoQ
The price to book (P/B) is 37% lower than the 5-year quarterly average of 6.2 and 20% lower than the last 4 quarters average of 4.9
The P/S is 93% below the 5-year quarterly average of 96.5 and 65% below the last 4 quarters average of 19.3

Efficiency

How efficient is Blueprint Medicines business performance
The ROIC has soared by 162% YoY but it has decreased by 7% from the previous quarter
The company's return on assets has surged by 148% YoY but it fell by 10% QoQ
BPMC's return on equity has surged by 141% year-on-year but it is down by 12% since the previous quarter
Blueprint Medicines's return on sales has surged by 107% YoY and by 2.6% QoQ

Dividends

What is BPMC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BPMC.

Financial health

How did Blueprint Medicines financials performed over time
BPMC's total assets has surged by 78% year-on-year but it is down by 5% since the previous quarter
Blueprint Medicines's current ratio has increased by 18% from the previous quarter and by 16% YoY
BPMC's debt is 94% smaller than its equity
Blueprint Medicines's equity has surged by 105% YoY but it has decreased by 4.8% QoQ
BPMC's debt to equity has dropped by 57% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.